GSK1070806
Sponsors
GlaxoSmithKline, Cambridge University Hospitals NHS Foundation Trust, University of Birmingham
Conditions
Behcet's DiseaseCrohn DiseaseDermatitis, AtopicDiabetes MellitusInflammatory Bowel DiseasesKidney Transplantation (Status Post)
Phase 1
First Time in Human Study of Intravenous Interleukin-18 Antibody
CompletedNCT01035645
Start: 2010-01-05End: 2012-07-11Updated: 2017-06-12
A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease
CompletedNCT03681067
Start: 2019-02-20End: 2020-06-02Updated: 2021-04-28
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
CompletedNCT04975438
Start: 2021-11-18End: 2023-03-13Updated: 2025-08-28
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive
CompletedNCT05590338
Start: 2022-11-04End: 2023-12-28Updated: 2024-08-13
Phase 2
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM
CompletedNCT01648153
Start: 2012-08-31End: 2014-01-31Updated: 2016-11-21
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
TerminatedNCT02723786
Start: 2016-08-27End: 2018-03-06Updated: 2019-06-26
Anti IL-18 (GSK1070806) in Behcet's Disease
NCT03522662
Start: 2018-08-01End: 2020-04-01Target: 12Updated: 2018-05-11
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
TerminatedNCT05999799
Start: 2023-11-16End: 2025-07-23Updated: 2026-06-03
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
TerminatedNCT06447506
Start: 2024-06-05End: 2025-07-29Updated: 2026-06-16